{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-011031","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.073513+00:00","generated_at":"2026-06-14T02:18:56.833900+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Xilio Therapeutics stockholders elect three Class II directors, ratify Ernst & Young as auditor","bullets":["Daniel Curran, Robert Ross, and Yuan Xu elected as Class II directors for three-year terms through 2026.","Ratification of Ernst & Young as independent auditor for FY 2023: 21,955,354 for, 1,623 against, 230,537 abstain.","Broker non-votes of 3,812,216 recorded on each director election.","Annual meeting held June 8, 2023; all proposals passed with strong support."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-011031","json":"https://secwatch.observer/filing/0001558370-23-011031.json","markdown":"https://secwatch.observer/filing/0001558370-23-011031.md","text":"https://secwatch.observer/filing/0001558370-23-011031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023011031/0001558370-23-011031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023011031/xlo-20230608x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T02:18:56.833900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51252ce150eaf277efc3681ebc05d59b23bf3d00","claim":"Xilio Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-08 meeting.","evidence_excerpt":"2. The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023011031/0001558370-23-011031-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-08"}],"fact_type":"shareholder_vote"},{"claim_id":"5a2275be49c6b2d80397fcac1d5b7e38348a9e0e","claim":"Xilio Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2023-06-08 meeting.","evidence_excerpt":"1. The Company’s stockholders elected Daniel Curran, M.D., Robert Ross, M.D., and Yuan Xu, Ph.D., as Class II directors, each to serve for a three-year term expiring at the 2026 annual meeting of stockholders and until his or her successor has been duly elected and qualified.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023011031/0001558370-23-011031-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-08"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}